HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.

AbstractSTATEMENT OF PROBLEM:
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of the cases. Good response to hormone treatment has been documented, although its use remains controversial. The aim of this study was to examine the efficacy of an anti-estrogenic agent, tamoxifen, in the treatment of HHT-associated epistaxis.
METHOD OF STUDY:
Out of 46 patients with diagnosis of epistaxis due to HHT who started treatment with tamoxifen 20 mg/d, 38 patients completed a mean of 23.4 months of treatment. All patients filled out a self-assessment questionnaire of rhinologic Quality of Life and epistaxis grading scale.
MAIN RESULTS:
The bleeding score and the Quality of Life score improved. Hemoglobin concentration also improved. None of the patients needed blood transfusions during the treatment period. Only one patient had minor side effects of the drug.
PRINCIPAL CONCLUSIONS:
Tamoxifen appears to be an effective agent for the treatment of epistaxis due to HHT.
AuthorsE Yaniv, M Preis, J Shevro, B Nageris, T Hadar
JournalRhinology (Rhinology) Vol. 49 Issue 2 Pg. 214-6 (Jun 2011) ISSN: 0300-0729 [Print] Netherlands
PMID21743879 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Estrogen Antagonists
  • Tamoxifen
Topics
  • Adult
  • Epistaxis (drug therapy, etiology)
  • Estrogen Antagonists (therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quality of Life
  • Tamoxifen (therapeutic use)
  • Telangiectasia, Hereditary Hemorrhagic (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: